Todd R. Kornfeld focuses his practice on a range of corporate matters, including capital markets, corporate governance, securities compliance, venture capital and cryptocurrencies. He represents clients in the life sciences, biotechnology, asset management and technology industries.
Todd represents public and private life sciences and biotech companies in connection with a variety of capital markets transactions, including IPOs, follow-on offerings, PIPEs, RDOs and private placements. He also handles matters involving Securities Exchange Act compliance, venture capital, corporate governance, stock exchange listing, broker-dealer matters and general corporate representation.
Todd represents hedge fund managers as well as investors, issuers and fiduciaries with digital asset matters, including Bitcoin, Ether, Tether and other proof-of-work, proof-of-stake, and stablecoin cryptocurrencies. He is particularly well-versed in the emerging regulatory framework around digital assets and in applying existing securities and commodities laws.
In addition, Todd represents issuers and borrowers in various industries with derivative transactions, including interest rate swaps and equity derivatives used for synthetic public offerings and hedging. Todd works closely with hedge funds and other asset managers on fund formation, Commodity Exchange Act registration, and the Investment Advisers Act, as well as with FinTech platforms relating to broker-dealer and other securities law issues. Todd has extensive experience representing issuers, placement agents, and investment managers with various structured finance products, including CLOs, CDOs, CMBS and credit-linked notes.
- Legal 500 US, Recommended, 2025
- New York University School of Law, LLM
- Boston University School of Law, JD, magna cum laude
- State University of New York at Albany, BS
- New York
Insights, News & Events
Article / September 15, 2025
Rethinking transparency: How CRL publication could reshape sponsor disclosures
Article / December 3, 2024
Key Takeaways | Alternative Capital-Raising Strategies in Challenging Times
Deal announcement / October 28, 2024
McDermott Represents Inhibikase Therapeutics in its Financing of Up to $275 Million
Deal announcement / August 9, 2024
McDermott Represents Waller Helms Advisors, LLC in Sale to Houlihan Lokey Inc.
Deal announcement / July 18, 2024
McDermott Represents Applied DNA Sciences, Inc. in its $12 Million Public Offering
Deal announcement / July 18, 2024
McDermott Represents Inhibikase Therapeutics in its $4 Million Registered Direct Offering
Article / May 22, 2024
Supreme Court: Pure Omissions Cannot Support Rule 10b-5(b) Liability
London – 22 Bishopsgate / Law360 / May 9, 2024
Article / May 22, 2024
Supreme Court: Pure Omissions Cannot Support Rule 10b-5(b) Liability
Article / April 17, 2024
Dual Track Reboot: Five Key Considerations for Supercharging Your Life Science Company ...
Video / June 2023
Video / June 2023
Video | Early-Stage Healthcare: Standing Out and Getting Funded
Deal announcement / October 28, 2024
McDermott Represents Inhibikase Therapeutics in its Financing of Up to $275 Million
Deal announcement / August 9, 2024
McDermott Represents Waller Helms Advisors, LLC in Sale to Houlihan Lokey Inc.
Deal announcement / July 18, 2024
McDermott Represents Applied DNA Sciences, Inc. in its $12 Million Public Offering
Deal announcement / July 18, 2024
McDermott Represents Inhibikase Therapeutics in its $4 Million Registered Direct Offering
London – 22 Bishopsgate / Law360 / May 9, 2024
Deal announcement / February 6, 2024
McDermott Represents Applied DNA Sciences, Inc. in Registered Direct Offering
Disclaimer
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott Will & Schulte via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott Will & Schulte from representing any other person or firm in any matter; and will not obligate McDermott Will & Schulte to keep confidential the information you provide. McDermott Will & Schulte cannot enter into an attorney-client relationship with you until McDermott Will & Schulte has determined that doing so will not create a conflict of interest and until you and McDermott Will & Schulte have entered into a written agreement or engagement letter that sets forth the terms of our relationship.